All Programs

Use the tool below to view all available Series

Pulmonary Hypertension: Comorbidities With PAH and Group 2 PH
Pulmonary Hypertension: Comorbidities With PAH and Group 2 PH
CME/CE Broadcast Replay
Pulmonary Hypertension: Comorbidities With PAH and Group 2 PH
1.00 credit
- Vallerie V. McLaughlin, MD
- Thomas Cascino, MD
- Bradley A. Maron, MD
1.00 credit
Pulmonary Hypertension Management: Practice Trends and Updates
Pulmonary Hypertension Management: Practice Trends and Updates
CME/CE Broadcast Replay
Pulmonary Hypertension Management: Practice Trends and Updates
1.00 credit
- Vallerie V. McLaughlin, MD
- Victor Moles, MD
- Ioana Preston, MD
1.00 credit
FCS and SHTG: Are We Meeting the Need?
FCS and SHTG: Are We Meeting the Need?
CME/CE
FCS and SHTG: Are We Meeting the Need?
0.25 credits
- Ira J. Goldberg, MD
- Kausik Ray, MBChB, MD, MPhil
- Christie Ballantyne
0.25 credits
Novel oral LDL-c lowering therapies on the horizon: CETP inhibition
Novel oral LDL-c lowering therapies on the horizon: CETP inhibition
MinuteCE®
Novel oral LDL-c lowering therapies on the horizon: CETP inhibition
0.75 program credits
- Ulrich Laufs, MD, PhD
0.75 program credits
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
MinuteCE®
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
0.75 program credits
- Pasquale Perrone-Filardi, MD, PhD
0.75 program credits
Challenges of managing hyperkalemia in HF patients with CKD while maintaining RAAS inhibitor therapy
Challenges of managing hyperkalemia in HF patients with CKD while maintaining RAAS inhibitor therapy
MinuteCE®
Challenges of managing hyperkalemia in HF patients with CKD while maintaining RAAS inhibitor therapy
0.75 program credits
- Gianluigi Savarese, MD
0.75 program credits
The remaining challenges in lowering LDL-c in patients at increased CV risk
The remaining challenges in lowering LDL-c in patients at increased CV risk
MinuteCE®
The remaining challenges in lowering LDL-c in patients at increased CV risk
0.75 program credits
- Prof. Kausik Ray
0.75 program credits
MinuteCE®
Strategies for managing hyperkalemia in cardiorenal disease: A clinical dialogue defining a roadmap to improved outcomes
0.75 credits 3 episodes
- Gianluigi Savarese, MD
- James Burton, DM, FRCP
- Aaron Wong, MD
0.75 credits 3 episodes
Summarizing multidisciplinary strategies: Where do we go from here?
Summarizing multidisciplinary strategies: Where do we go from here?
MinuteCE®
Summarizing multidisciplinary strategies: Where do we go from here?
0.75 program credits
- Gianluigi Savarese, MD
0.75 program credits
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
CME/CE
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
0.50 credits
- Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
- Scott Solomon, MD
- Mikhail Kosiborod, MD
0.50 credits
Managing a patient with residual risk: Applying recent evidence with EPA to practice
Managing a patient with residual risk: Applying recent evidence with EPA to practice
MinuteCE®
Managing a patient with residual risk: Applying recent evidence with EPA to practice
0.50 program credits
- Prof. Kausik Ray
0.50 program credits
A novel CETP inhibitor to target CV risk reduction: Where could it fit in future lipid management?
A novel CETP inhibitor to target CV risk reduction: Where could it fit in future lipid management?
MinuteCE®
A novel CETP inhibitor to target CV risk reduction: Where could it fit in future lipid management?
0.50 program credits
- Erin Michos
0.50 program credits
Understanding the role of triglycerides in the assessment of residual risk
Understanding the role of triglycerides in the assessment of residual risk
MinuteCE®
Understanding the role of triglycerides in the assessment of residual risk
0.50 program credits
- Prof. Alberto Zambon MD, PhD, FAHA
0.50 program credits
CETP inhibition: Lessons from two decades of clinical trials
CETP inhibition: Lessons from two decades of clinical trials
MinuteCE®
CETP inhibition: Lessons from two decades of clinical trials
0.50 program credits
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
0.50 program credits
Integrating EPA in CV risk reduction strategies: Practical experience and guidance
Integrating EPA in CV risk reduction strategies: Practical experience and guidance
MinuteCE®
Integrating EPA in CV risk reduction strategies: Practical experience and guidance
0.50 program credits
- Azfar Zaman, MD
0.50 program credits
Understanding the etiology of HCM and pathways for intervention
Understanding the etiology of HCM and pathways for intervention
MinuteCE®
Understanding the etiology of HCM and pathways for intervention
0.75 program credits
- Roberto Barriales-Villa, MD, PhD
0.75 program credits

All Programs

Popular

Title

Share on ReachMD